Alzheimer's disease (AD) is a neurodegenerative disorder primarily affecting regions of the brain responsible for higher cognitive functions. Immunization against -amyloid (A) in animal models of AD has been shown to be effective on the molecular level but also on the behavioral level. Recently, we reported naturally occurring autoantibodies against A (NAbs-A) being reduced in Alzheimer's disease patients. Here, we further investigated their physiological role: in epitope mapping studies, NAbs-A recognized the mid-/Cterminal end of A and preferentially bound to oligomers but failed to bind to monomers/fibrils. NAbs-A were able to interfere with A peptide toxicity, but NAbs-A did not readily clear senile plaques although early fleecy-like plaques were reduced. Administration of NAbs-A in transgenic mice improved the object location memory significantly, almost reaching performance levels of wild-type control mice. These findings suggest a novel physiological mechanism involving NAbs-A to dispose of proteins or peptides that are prone to forming toxic aggregates.